Wilson Sonsini Goodrich & Rosati has advised Denali Therapeutics. Davis Polk has advised the representatives of the several underwriters. Denali Therapeutics Inc. (Nasdaq: DNLI) has completed...
Denali Therapeutics Completes $200 Million Public Offering of Common Stock and Pre-Funded Warrants
Check Point Completes $2 Billion Convertible Senior Notes Offering
Wilson Sonsini Goodrich & Rosati have advised Check Point Software Technologies Ltd.; Latham & Watkins, with Meitar as Israeli counsel, have advised the initial purchasers. Check...
Denali Therapeutics’ $500 Million Private Placement Financing
Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics Inc. on the transaction. Denali Therapeutics (Nasdaq: DNLI) announced that it entered into a securities purchase agreement with...
Denali Therapeutics’ $316 Million Public Offering
Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the deal, while Davis Polk advised the representatives of the several underwriters. Denali Therapeutics, a biopharmaceutical company...
Blend’s IPO
Wilson Sonsini Goodrich & Rosati advised Blend on the deal while Goodwin Procter represented the underwriters. Blend Labs, Inc. announced the pricing of its initial public...
Marqeta’s $1.2 Billion IPO
Wilson Sonsini Goodrich & Rosati advised the underwriters on the deal while Goodwin Procter LLP represented Marqeta, Inc. Marqeta announced the pricing of its initial public...
ThredUp Inc.’s $168 Million IPO
Wilson Sonsini Goodrich & Rosati advised the underwriters on the deal. ThredUp Inc. (thredUP) announced the pricing of its initial public offering of 12,000,000 shares of...